Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States

2008 ◽  
Vol 44 (4) ◽  
pp. 579-587 ◽  
Author(s):  
Milena Sant ◽  
Claudia Allemani ◽  
Roberta De Angelis ◽  
Antonino Carbone ◽  
Silvia de SanJosè ◽  
...  
2012 ◽  
Author(s):  
Meredith S. Shiels ◽  
Eric A. Engels ◽  
Christina Clarke ◽  
H. Irene Hall ◽  
Patricia Hartge ◽  
...  

2019 ◽  
pp. 1-10
Author(s):  
Rafil T. Yaqo ◽  
Sana D. Jalal ◽  
Kharaman J. Ghafour ◽  
Hemin A. Hassan ◽  
Michael D. Hughson

PURPOSE In the Middle East, incidence rate ratios (IRRs) of non-Hodgkin lymphoma (NHL) to Hodgkin lymphoma (HL) are more than 50% lower than the United States. MATERIALS AND METHODS Age-specific incidence rates (ASIRs), age-adjusted incidence rates (AAIRs), and IRRs of NHL:HL were compared using the cancer registries of Iraq, Jordan, Saudi Arabia, and US SEER. RESULTS The NHL AAIR (95% CI) per 100,000 population was 4.4 (4.1 to 4.7) for Iraq, 5.4 (4.6 to 6.2) for Jordan, 4.7 (4.4 to 5.1) for Saudi Arabia, and 13.2 (13.0 to 13.4) for the United States. The HL AAIR was 1.8 (1.6 to 2.0) for Iraq, 1.8 (1.4 to 2.2) for Jordan, 2.1 (1.9 to 2.2) for Saudi Arabia, and 2.3 (2.2 to 2.4) for the United States, with respective NHL:HL IRR of 2.4 (2.2 to 2.7), 3.0 (2.4 to 3.8), 2.2 (2.0 to 2.5), and 5.7 (5.5 to 6.0). NHL ASIRs for the Middle East and the United States were similar until 30 to 39 years of age. Thereafter, ASIR of NHL peaked at 20 to 33 per 100,000 at age 70 years in the Middle East regions, all much lower than the US age 70 years rate of greater than 100 per 100,000. Diffuse large B-cell lymphoma (DLBCL) represented 52% of NHL in Sulaimaniyah Province of Iraq and 51% of NHL in Saudi Arabia. Both regions had AAIR for DLBCL less than 42% of DLBCL in US SEER. Pediatric Epstein-Barr virus–related Burkitt’s lymphoma at 8% was the second most frequent NHL in Sulaimaniyah but made little contribution to overall NHL rates. CONCLUSION The incidence of HL was slightly lower than in the United States, but it was the markedly lower rates of adult NHL with advancing age, including the predominant DLBCL, that accounted for the low NHL:HL IRR in these Middle Eastern countries.


2016 ◽  
Vol 34 (27) ◽  
pp. 3276-3283 ◽  
Author(s):  
Elizabeth L. Yanik ◽  
Chad J. Achenbach ◽  
Satish Gopal ◽  
Anna E. Coghill ◽  
Stephen R. Cole ◽  
...  

Purpose The biology of HIV-associated cancers may differ depending on immunologic and virologic context during development. Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral therapy (ART), virologic suppression, and CD4 count is important. Patients and Methods KS and NHL diagnoses during 1996 to 2011 were identified among patients with HIV infection in eight clinical cohorts in the United States. Among patients in routine HIV clinical care, the proportion of cases in categories of ART use, HIV RNA, and CD4 count at diagnosis were described across calendar time. Person-time and incidence rates were calculated for each category. Results We identified 466 patients with KS and 258 with NHL. In recent years, KS was more frequently diagnosed after ART initiation (55% in 1996 to 2001 v 76% in 2007 to 2011; P-trend = .02). The proportion of patients with NHL who received ART was higher but stable over time (83% overall; P-trend = .81). An increasing proportion of KS and NHL occurred at higher CD4 counts (P < .05 for KS and NHL) and with undetectable HIV RNA (P < .05 for KS and NHL). In recent years, more person-time was contributed by patients who received ART, had high CD4 counts and had undetectable HIV RNA, whereas incidence rates in these same categories remained stable or declined. Conclusion Over time, KS and NHL occurred at higher CD4 counts and lower HIV RNA values, and KS occurred more frequently after ART initiation. These changes were driven by an increasing proportion of patients with HIV who received effective ART, had higher CD4 counts, and had suppressed HIV RNA and not by increases in cancer risk within these subgroups. An improved understanding of HIV-associated cancer pathogenesis and outcomes in the context of successful ART is therefore important.


Cancer ◽  
2017 ◽  
Vol 123 (23) ◽  
pp. 4663-4671 ◽  
Author(s):  
Elizabeth L. Yanik ◽  
Meredith S. Shiels ◽  
Jodi M. Smith ◽  
Christina A. Clarke ◽  
Charles F. Lynch ◽  
...  

2004 ◽  
Vol 96 (18) ◽  
pp. 1368-1374 ◽  
Author(s):  
E. A. Engels ◽  
R. P. Viscidi ◽  
D. A. Galloway ◽  
J. J. Carter ◽  
J. R. Cerhan ◽  
...  

2016 ◽  
Vol 25 (9) ◽  
pp. 1289-1296 ◽  
Author(s):  
Nadia Howlader ◽  
Meredith S. Shiels ◽  
Angela B. Mariotto ◽  
Eric A. Engels

2012 ◽  
Vol 2012 ◽  
pp. 1-27 ◽  
Author(s):  
Bryan A. Bassig ◽  
Qing Lan ◽  
Nathaniel Rothman ◽  
Yawei Zhang ◽  
Tongzhang Zheng

The incidence rates of non-Hodgkin lymphoma (NHL) have steadily increased over the last several decades in the United States, and the temporal trends in incidence can only be partially explained by the HIV epidemic. In 1992, an international workshop sponsored by the United States National Cancer Institute concluded that there was an “emerging epidemic” of NHL and emphasized the need to investigate the factors responsible for the increasing incidence of this disease. Over the past two decades, numerous epidemiological studies have examined the risk factors for NHL, particularly for putative environmental and lifestyle risk factors, and international consortia have been established in order to investigate rare exposures and NHL subtype-specific associations. While few consistent risk factors for NHL aside from immunosuppression and certain infectious agents have emerged, suggestive associations with several lifestyle and environmental factors have been reported in epidemiologic studies. Further, increasing evidence has suggested that the effects of these and other exposures may be limited to or stronger for particular NHL subtypes. This paper examines the progress that has been made over the last twenty years in elucidating the etiology of NHL, with a primary emphasis on lifestyle factors and environmental exposures.


Cancer ◽  
2012 ◽  
Vol 118 (19) ◽  
pp. 4842-4850 ◽  
Author(s):  
Chadi Nabhan ◽  
Michelle Byrtek ◽  
Michael D. Taylor ◽  
Jonathan W. Friedberg ◽  
James R. Cerhan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document